Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P435 | DOI: 10.1530/endoabs.35.P435

ECE2014 Poster Presentations Diabetes complications (59 abstracts)

Hemostatic biomarkers in selected group of patients with type 1 diabetes: are they associated with different degrees of diabetic retinopathy

Sefika Burcak Polat 1 , Nagihan Ugurlu 2 , Fatma Yulek 2 , Huseyin Simavli 3 , Reyhan Ersoy 1 , Ozcan Erel 4 & Bekir Cakir 1


1Yildirim Beyazit University, Ataturk Education and Research Hospital, Endocrinology and Metabolism Department, Ankara, Turkey; 2Yildirim Beyazit University, Ataturk Education and Research Hospital, Ophtalmology Department, Ankara, Turkey; 3Bolu, Izzet Baysal Hospital, Ophthalmology Department, Bolu, Turkey; 4Bolu Izzet Baysal University Hospital, Biochemistry Department, Ankara, Turkey.


Background: Diabetic retinopathy (DR) is the leading cause of blindness in the world. Retinopathy and nephropathy can still progress in diabetics despite optimal metabolic control. The aim of the present study was to determine whether different degrees of DR (proliferative or non-proliferative) were associated with abnormally modulated hemostatic parameters in patients with type 1 DM.

Method: 52 type 1 diabetic patients and 40 healthy controls were enrolled in the study. Patients were then subdivided into three categories. Group I was defined as those without retinopathy, Group II with NPRP, and Group III with PRP. We have compared these subgroups with each other and the control group (Group IV) according to the serum fibrinogen, plasminogen, α2-anti-plasmin, and PAI.

Results: We detected that PAI-1 levels were higher in the diabetic groups than control, but this was not statistically significant whereas serum fibrinogen (P=0.224) and plasminogen (P=0.224) were similar between the diabetic and control groups. α-2-Anti-plasmin in Groups I, II, and III was higher compared to the control group (P<0.01, P<0.05, and P<0.001 respectively) and the positive correlation identified between serum α2-anti-plasmin and HbA1c levels (r=0.268, P=0.031).

Conclusion: To our knowledge there are only a small number of studies measuring α2-antiplasmin levels in type 1 diabetes. A positive correlation between α2-anti-plasmin with HbA1c suggests that fibrinolytic markers may improve with disease regulation, and better glycemic control. High α2-anti-plasmin level might be a novel a risk factor for development of DR. Confirmation of these data would allow a better understanding of the pathogenesis of DR.

Article tools

My recent searches

No recent searches.